LPTX Stock Forecast 2025-2026
Distance to LPTX Price Targets
LPTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Leap Therapeutics (LPTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LPTX and similar high-potential opportunities.
Latest LPTX Stock Price Targets & Analyst Predictions
LPTX has shown a year-to-date change of -87.5% and a 1-year change of -86.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for LPTX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LPTX Analyst Ratings
LPTX Price Target Range
Latest LPTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LPTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 29, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $0.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.50 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.50 |
| Aug 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.50 |
| Jun 28, 2024 | Rodman & Renshaw | Tony Butler | Buy | Initiates | $8.00 |
| May 14, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $5.50 |
| Mar 19, 2024 | Baird | Joel Beatty | Outperform | Maintains | $9.00 |
| Mar 19, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Nov 20, 2023 | Mizuho | Mara Goldstein | Buy | Maintains | $12.00 |
| Nov 14, 2023 | Raymond James | Steven Seedhouse | Outperform | Maintains | $17.50 |
| Aug 15, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $7.00 |
| Aug 15, 2023 | Baird | Joel Beatty | Outperform | Maintains | $20.00 |
| Jul 13, 2023 | Raymond James | Steven Seedhouse | Outperform | Maintains | $18.50 |
| Jun 23, 2023 | Raymond James | Steven Seedhouse | Outperform | Maintains | $17.00 |
| May 16, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
| Apr 13, 2023 | Mizuho | Mara Goldstein | Buy | Reiterates | $2.00 |
| Mar 27, 2023 | Raymond James | Steven Seedhouse | Outperform | Maintains | $2.00 |
| Mar 27, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $2.50 |
| Mar 17, 2023 | Mizuho | Mara Goldstein | Buy | Maintains | $2.00 |
| Jan 27, 2023 | Mizuho | Mara Goldstein | Buy | Maintains | $3.00 |
Leap Therapeutics, Inc. (LPTX) Competitors
The following stocks are similar to Leap Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Leap Therapeutics, Inc. (LPTX) Financial Data
Leap Therapeutics, Inc. has a market capitalization of $17.38M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -107.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Leap Therapeutics, Inc. (LPTX) Business Model
About Leap Therapeutics, Inc.
Develops innovative cancer therapies using immunotherapy.
Leap Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of monoclonal antibody treatments that harness the immune system to target cancer cells. The company generates revenue through the advancement of its drug candidates, which may eventually be commercialized through partnerships, licensing agreements, or direct sales upon successful clinical trials and regulatory approvals.
The company is particularly focused on treating challenging cancers with limited options, such as mesothelioma, ovarian, and pancreatic cancers. Leap Therapeutics positions itself in the fast-evolving biopharmaceutical sector, emphasizing personalized medicine and innovative treatment approaches to improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
54
CEO
Mr. Douglas E. Onsi J.D.
Country
United States
IPO Year
2017
Website
www.leaptx.comLeap Therapeutics, Inc. (LPTX) Latest News & Analysis
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
2 months agoSirexatamab (DKN-01) shows a 35% objective response rate in second-line colorectal cancer patients, surpassing the 23% rate in the control group. Phase 3 study preparations are underway.
The 35% ORR for sirexatamab in CRC indicates promising efficacy, potentially attracting investor interest and impacting stock valuations for the involved biotech firms.
Leap Therapeutics, Inc. (Nasdaq: LPTX) announced a leadership update involving Douglas E. on January 6, 2025. The company specializes in targeted and immuno-oncology therapeutics.
Leadership changes can impact a company's strategic direction and investor confidence. Douglas E.'s appointment may influence Leap Therapeutics' future performance and stock valuation.
Leap Therapeutics is developing DKN-01 for solid tumors, with positive early GI cancer trial results. However, LPTX has less than a year of funds, raising funding concerns ahead of key 2025 trial readouts.
Leap Therapeutics' limited funding and upcoming phase 2 trial results for DKN-01 in 2025 could lead to significant valuation shifts, affecting investment decisions and stock performance.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced a leadership change with Douglas E. taking a new position, signaling potential strategic developments in their oncology therapeutics focus.
Leap Therapeutics' announcement may signal leadership changes or strategic shifts, impacting investor confidence and stock performance in the biotech sector.
Leap Therapeutics, Inc. (Nasdaq: LPTX) reported its financial results for Q3 2024, focusing on its development of targeted and immuno-oncology therapeutics.
Leap Therapeutics' Q3 financial results can indicate its operational health and growth potential, impacting stock performance and investor sentiment in the biotech sector.
Leap Therapeutics has completed enrollment of 188 patients in the DeFianCe study's Part B, testing DKN-01 with bevacizumab and chemotherapy for advanced colorectal cancer.
Completion of patient enrollment in a key clinical trial for DKN-01 may signal potential advancements in treatment options, influencing Leap Therapeutics' stock performance and investor sentiment.
Frequently Asked Questions About LPTX Stock
What is Leap Therapeutics, Inc.'s (LPTX) stock forecast for 2025?
Analyst forecasts for Leap Therapeutics, Inc. (LPTX) are not currently available. The stock is trading at $0.36.
Is LPTX stock a good investment in 2025?
According to current analyst ratings, LPTX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LPTX stock?
Price predictions from Wall Street analysts for LPTX are not currently available. The stock is trading at $0.36.
What is Leap Therapeutics, Inc.'s business model?
Leap Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of monoclonal antibody treatments that harness the immune system to target cancer cells. The company generates revenue through the advancement of its drug candidates, which may eventually be commercialized through partnerships, licensing agreements, or direct sales upon successful clinical trials and regulatory approvals.
What is the highest forecasted price for LPTX Leap Therapeutics, Inc.?
Price targets from Wall Street analysts for LPTX are not currently available. The stock is trading at $0.36.
What is the lowest forecasted price for LPTX Leap Therapeutics, Inc.?
Price targets from Wall Street analysts for LPTX are not currently available. The stock is trading at $0.36.
What is the overall LPTX consensus from analysts for Leap Therapeutics, Inc.?
The overall analyst consensus for LPTX is neutral. Out of 8 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are LPTX stock price projections?
Stock price projections, including those for Leap Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
